Save Product
Product Details
Synonyms
Complement C5, C5, CPAMD4
Source
Cynomolgus Complement C5, His Tag (CO5-C52Hx) is expressed from human 293 cells (HEK293). It contains AA Gln 19 - Cys 1676 (Accession # XP_005580972.1).
Predicted N-terminus: Gln 19 (β chain) & Met 678 (α chain)
Request for sequenceMolecular Characterization
Other Tags and Version Biotin & Other Labeled Version
This protein carries a polyhistidine tag at the C-terminus. The mature form of Complement C5 is a disulfide-linked heterodimer composed of proteolytically cleaved α and β chain. Each α and β chain has a calculated MW of 73.9 kDa (β chain) and 114.9 kDa (α chain). The protein migrates as 65 kDa and 113 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
Endotoxin
Less than 1.0 EU per μg by the LAL method / rFC method.
Purity
>95% as determined by SDS-PAGE.
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Shipping and Storage
This product is shipped at ambient temperature.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Customers Also Viewed
Performance Data
SDS-PAGE
Cynomolgus Complement C5, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).
SEC-MALS
The purity of Cynomolgus Complement C5, His Tag (Cat. No. CO5-C52Hx) is more than 85% and the molecular weight of this protein is around 175-215 kDa verified by SEC-MALS.
Report
Bioactivity-ELISA
Immobilized Cynomolgus Complement C5, His Tag (Cat. No. CO5-C52Hx) at 2 μg/mL (100 μL/well) can bind Anti-C5a (Human IgG1) with a linear range of 0.4-6 ng/mL (QC tested).
Protocol
Immobilized Cynomolgus Complement C5, His Tag (Cat. No. CO5-C52Hx) at 2 μg/mL (100 μL/well) can bind Eculizumab Biosimilar with a linear range of 0.5-31 ng/mL (Routinely tested).
Protocol
Customer Reviews Writing Reviews
1***32022-08-10
LikesI tried to express this product myself and it didn’t work, so I purchased ACRO’s products for antibody screening. The binding activity is very good and method establishment is also going very smoothly. There is also complete technical support available to help us solve any problems that arise during our experiments.
FAQ
- product
Can lyophilized proteins remain stable during room-temperature shipping or temporary room-temperature exposure?
In general, lyophilized proteins remain stable during room-temperature shipping or temporary exposure to room-temperature conditions.
Many ACROBiosystems recombinant proteins are supplied in lyophilized (freeze-dried) form. The lyophilization process effectively removes moisture from the product, helping reduce degradation-related reactions and improve protein stability during transportation and storage.
To evaluate the stability of lyophilized proteins under normal temperature conditions, ACROBiosystems conducted a stability study on 11 representative lyophilized protein products at 37°C. The study demonstrated that these proteins maintained good quality stability after storage at 37°C for approximately 20 days. Based on these validation results, temporary room-temperature exposure during shipping or handling is generally not expected to have a significant impact on product quality or downstream application performance.
To ensure optimal long-term stability, products should be stored according to the storage conditions specified in the product Certificate of Analysis (COA) upon receipt.
Supporting Document
Background
Recent Advances
Drug Development Progress- English Name：
Complement C5
- Category：
- Approved Drugs：
8 Details
- Drugs in Clinical Trials：
20 Details
- Highest Development Stage：
Approved
Contact Us
Drug Candidate Licensing
